Efficacy and safety of empagliflozin to reduce atrial fibrillation episodes: systematic review
Abstract
Atrial fibrillation (AF) is a prevalent arrhythmia with significant morbidity and mortality. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, like empagliflozin, have demonstrated cardioprotective benefits, but their specific efficacy for reducing AF episodes has not been systematically evaluated. This systematic review aimed to synthesize the existing evidence on the efficacy and safety of empagliflozin for reducing atrial fibrillation episodes across various patient populations. A comprehensive search was conducted from 2020 to 2025, following PRISMA guidelines. Studies that assessed the impact of empagliflozin on AF incidence, recurrence, burden, or post-operative AF (POAF). Six studies were included, indicating that empagliflozin significantly reduce the composite risk of cardiovascular death or heart failure hospitalization in patients with and without pre-existing AF, with a larger absolute benefit in high-risk AF subgroups. For specific AF outcomes, a trend towards reduced POAF was observed, alongside a significant reduction in post-operative ventricular arrhythmias and inflammation. One real-world study suggested a potential difference in AF efficacy within the SGLT2 inhibitor class, favoring dapagliflozin. The safety profile of empagliflozin was consistent with its known pharmacology and was not associated with increased serious adverse events, even in surgical populations. The empagliflozin demonstrated a beneficial effect on reducing AF-related complications,…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.